Table 4. Location and timing of first recurrence in 14 of 60 (23%) patients following a pathologic complete response to neoadjuvant chemotherapy±radiation therapy for gastric or gastrooesophageal junction adenocarcinoma.

Recurrence location	Time to recurrence (months)	Treatment	Status at last follow-up	Time from recurrence to death or last follow-up (months)
CNS	15	None	DOD	1
CNSa	5	Whole brain RT	DOD	17
CNS	13	Surgery	DOD	26
CNS	6	Whole brain RT	DOD	2
CNS, livera	24	None	DOD	2
Liver	5	Platinum/CPT11	DOD	12
Lung	54	Platinum/Taxol	AWD	38
Skin	4	FOLFIRI	DOD	16
Regional LN	19	Platinum/Taxol	AWD	27
Regional LN	11	Taxol	DOD	36
Local	20	Taxol	DOD	24
Local	14	Surgery	DOD	1
Local	6	Taxol/CPT11	DOD	11
Local	15	Taxol/CPT11	DOD	10

Abbreviations: AWD=alive with disease; DOD=died of disease; CNS=central nervous system; FOLFIRI=5-FU+leucovorin+irinotecan; LN=lymph node; RT=radiation therapy.

^aDenotes gastric primary.